$GILD Headlines Trade what you see, not what you

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2014 at 1:47 PM

$GILD Headlines

Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Gilead Sovaldi sales reach $3.48B, ahead of $2.87B view 4:10 p.m. July 23, 2014 - Russ Britt
Gilead's $6.53B in revs. beats $5.85B estimate 4:10 p.m. July 23, 2014 - Russ Britt

Gilead Sciences Is Not Done Running 10:04 a.m. Today - Seeking Alpha
Biotechnology, Oil And Brazil ETFs To Watch This Week 9:05 a.m. Today - Benzinga.com
Ambit Biosciences (AMBI) Jumps: Stock Up 6.6% - Tale of the Tape 9:04 a.m. Today - Zacks.com
Mike Khouw's Gilead Sciences Trade 10:20 a.m. Aug. 30, 2014 - benzinga.com
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog 6:30 p.m. Aug. 29, 2014 - Zacks.com
Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog 6:10 p.m. Aug. 29, 2014 - Zacks.com
Intellipharmaceutics' Oxycodone Program to Prevent Overdose - Analyst Blog 5:10 p.m. Aug. 29, 2014 - Zacks.com
Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog 5:00 p.m. Aug. 29, 2014 - Zacks.com
Isis Pharmaceuticals Starts Phase III Study on ISIS-APOCIIIRx - Analyst Blog 4:55 p.m. Aug. 29, 2014 - Zacks.com
Momenta-Sandoz's Generic Copaxone Accepted for Review by FDA - Analyst Blog 3:20 p.m. Aug. 29, 2014 - Zacks.com
What You Need to Know About the Roche-InterMune Deal 2:51 p.m. Aug. 29, 2014 - benzinga.com
4 Biotechs That Might Be Bought Soon 10:53 a.m. Aug. 29, 2014 - Investors Business Daily
Market Posts Best August In 14 Years. Why Don't Investors Feel Better? 10:30 a.m. Aug. 29, 2014 - Seeking Alpha
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale of the Tape 9:11 a.m. Aug. 29, 2014 - Zacks.com
Why Gilead Sciences (GILD) Could Be Positioned for a Surge? - Tale of the Tape 8:53 a.m. Aug. 29, 2014 - Zacks.com
OncoMed Pharmaceuticals (OMED) in Focus: Stock Up 9.9% - Tale of the Tape 8:51 a.m. Aug. 29, 2014 - Zacks.com
Today's Market: Red Hot Biotech And Big Pharma Names To Watch 8:22 a.m. Aug. 29, 2014 - Seeking Alpha
Bristol-Myers' Oral HCV Treatment Daklinza Gets EU Clearance - Analyst Blog 6:50 p.m. Aug. 28, 2014 - Zacks.com
RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog 6:40 p.m. Aug. 28, 2014 - Zacks.com
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog 6:20 p.m. Aug. 28, 2014 - Zacks.com

Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind 5:20 a.m. July 4, 2014 - PR Newswire - PRF
Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus 6:30 a.m. July 1, 2014 - PR Newswire - PRF
AIDSVu Releases New Maps that Depict Impact of HIV in American Cities 9:50 a.m. June 27, 2014 - BusinessWire - BZX
Top White House AIDS Official Visits San Francisco Clinic on National HIV Testing Day 9:00 a.m. June 27, 2014 - PR Newswire - PRF
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Sofosbuvir for Chronic Hepatitis C 3:01 a.m. June 27, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Abu Dhabi's Youth Orchestra: A Cultural Revolution

A New Dawn for Abu Dhabi's Musical Future Abu Dhabi's making some noise, and I don't mean just any kind of noise. We're talking about a symphony of opportunity. The Department of Culture and Tourism – Abu Dhabi just dropped big news—setting up a dedicated institution for the Youth Orchestra Abu Dhabi. This ain't just a pat on the cultural back; it's a whole new ball...

Nucor's Q3 2026 Earnings: Strong Growth Amid Steel Surge

Nucor's Solid Third Quarter Performance Nucor Corporation is flexing its muscles, reporting a robust third quarter for 2026. With net earnings hitting $1.32 billion and a diluted earnings per share of $5.80, the steel giant has shown it can more than hold its ground in a competitive market. Compare that to last quarter's $1.16 billion - we're seeing serious momentum....

HONOR X9e Pro Unveils with Massive Battery Power

Lighting Up the Sky: HONOR's Big Move Picture this: the Burj Khalifa in Dubai, world’s tallest building, flashing with the promise of a smartphone's monstrous battery. That’s what the fine folks at HONOR did, highlighting their X9e Pro and its mind-boggling 11,000mAh battery. Now, am I the only one who finds it more than a little audacious to leverage such a flashy...

Essential Oils Market Booms; Hits $29.52Bn by 2031

Essential Oils: Aromatherapy's New Frontier and Pharma Ally What’s the deal with essential oils? Well, it seems they’re not just for your neighbor’s pricey diffuser anymore. According to some fresh numbers, we're staring down a market worth nearly $30 billion by 2031. And it ain't all incense and hippie stores fueling this beast — we're talking a serious expansion...

Medline's Decade-Long WRAP Partnership: More Than Labels

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

Mission Bancorp Hits Record Earnings, Extends Buyback

Record-Breaking Quarter Amid Challenging Times When Mission Bancorp's earnings hit the tape today, the numbers were enough to catch anyone's eye—$9.2 million in net income for Q3 2026, a 6% increase from last year. That's not small potatoes, especially considering the economic fog we're navigating through. AJ Antongiovanni, holding the reins as CEO, credits the bank's...

Honeywell Aerospace Faces Lawsuit After Stock Tumbles 23%

Honeywell's Bumpy Ride Rattles Investors Something's brewing over at Honeywell Aerospace, Inc. (NASDAQ:HONA) and it's not your regular cup of joe. Investors, brace yourselves, because a securities fraud class action lawsuit is stacking up against them. With shares plummeting 23.16% in a whirlwind of a market day, it's kind of hard not to get a little riled up, isn't it?...

Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

SWI Compute's Bold Move: Transforming Power Into AI

The Power Play: From Grid to AI If you think turning megawatts into money-making machines is a stretch, think again. SWI Compute is daringly striding into this territory with the launch of its NVIDIA AI factories in Europe, backed by a hefty 3.6 gigawatts of secured power capacity. It's not just talk; they've got the juice, both in electricity and ambition, to boot....

Innventure Faces Legal Scrutiny Over DarkNX Debacle

Innventure’s Market Tumult: Unraveling the Drama Talk about a mess. Innventure Inc. (NASDAQ: INV) investors are likely feeling a sting sharper than a bee that's lost its hive after a painful 55% stock crash back in August 2026. The culprit? A scuttled project involving a shadowy partner, DarkNX, and a lot of questions about who knew what and when. A Puzzling...